Skip to main content

Initial Outcomes Comparable for Dupuytren Contracture Treatments

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 13, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, Feb. 12, 2024 -- For patients with Dupuytren contracture, initial outcomes are similar for surgery, needle fasciotomy, and collagenase, but outcomes are superior for surgery at two years, according to a study published online Feb. 12 in the Annals of Internal Medicine.

Mikko Petteri Räisänen, M.D., from Kuopio University Hospital in Finland, and colleagues compared the effectiveness of surgery, needle fasciotomy, and collagenase injection at three months and two years in a randomized superiority trial conducted at six public hospitals in Finland. A total of 302 patients with treatment-naive Dupuytren contracture were randomly assigned to receive surgery, needle fasciotomy, or collagenase (101, 101, and 100 patients, respectively).

Overall, 97 and 94 percent of participants completed the three-month and two-year follow-ups, respectively. The researchers found that at three months, success rates, defined as greater than 50 percent contracture released and reaching the patient acceptable symptom state, were similar (71, 73, and 73 percent for surgery, needle fasciotomy, and collagenase, respectively). Compared with both needle fasciotomy and collagenase, surgery had superior success at two years (78 percent versus 50 and 65 percent, respectively; adjusted risk differences, 0.30 and 0.13, respectively).

"Longer follow-up of study participants will determine whether the superior success rates of surgery persist as an increasing number of recurrences are addressed, and whether the lower rate of reinterventions with surgery can offset higher initial treatment expenses," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted February 2024

Read this next

ASCO: Neoadjuvant Ipilimumab + Nivolumab Ups Survival in Resectable Melanoma

WEDNESDAY, June 5, 2024 -- Neoadjuvant ipilimumab plus nivolumab followed by surgery results in longer event-free survival than surgery followed by adjuvant nivolumab among...

Odds of Death Lower With Surgery for Hip Fracture in Patients With Dementia

MONDAY, June 3, 2024 -- For community-dwelling patients with dementia and fracture of the femoral head and neck, the odds of death are lower for those treated surgically...

Emergency Inguinal Hernia Surgery Rates Increased With Lower Country Income

FRIDAY, May 31, 2024 -- For patients undergoing inguinal hernia surgery, emergency surgery rates increase from high- to low-income countries, according to a study published online...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.